Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 1997

View Archived Issues

Isis reports positive safety and efficacy profile for fomivirsen

Celgene describes TNF/PDE inhibitors

Atypical neuroleptics from Merck KGaA

Chiroscience prepares new class of peptidyl MMP and TNF-alpha inhibitors

Glaxo Wellcome describes optically active pyrimidine useful as analgesic and anticonvulsant

Pfizer reports prodrugs of NMDA antagonist

Diaziridinylpolyamines as anticancer agents claimed by U. of Maryland

Na+/H+ exchange inhibitors reported by Hoechst

VX-497: selective IMPDH inhibitor with potent immunosuppressive properties

Onyx reports clinical results of anticancer viral therapeutic at ASCO meeting

Antiplatelet effects of arbidol

Mylan receives FDA approval for generic etodolac

NMDA antagonist/opiate combination provides superior analgesia to morphine alone

Antibodies to interferon gamma alone and in combination for arthritis and SLE

UR-12670 effective in rat model of endotoxic shock

Encouraging results reported for ImClone's lead cancer therapeutic agent

Preliminary phase II and phase I/II results for Allovectin-7

Interim results with Pharmacyclics' Gd-Tex reported at ASCO

Pharmacyclics reports phase I results for Lu-Tex

FDA reschedules review date for Heart Laser

Malononitrilamides associated with potent immunosuppressive effects in animal models

Phase I results with Isis antisense anticancer drug reported at ASCO

Enrollment complete for phase II trial of lisofylline in AML

North American Vaccine cleared to initiate trials of meningitis vaccine

First launch for Quadramet

Alora launched in U.S.

GenESA System deemed approvable

Disappointing phase III results for Bayer anti-TNF antibody

Molecumetics and Asahi enter anticoagulant collaboration

Results from a comparative study of olanzapine and risperidone reported

Oxford GlycoSciences receives U.K. approval to commence trials on novel nucleoside analogue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...